BIOATLA INC BCAB
COM · Common Stock · CUSIP 09077B104
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersSan Diego, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $4.14.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 74 |
| Q4 2022 | 92 |
| Q1 2023 | 82 |
| Q2 2023 | 88 |
| Q3 2023 | 83 |
| Q4 2023 | 80 |
| Q1 2024 | 85 |
| Q2 2024 | 81 |
| Q3 2024 | 66 |
| Q4 2024 | 68 |
| Q1 2025 | 44 |
| Q2 2025 | 40 |
| Q3 2025 | 43 |
| Q4 2025 | 41 |
| Q1 2026 | 34 |
| Q2 2026 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2024 | 22 | 54 |
| Q4 2024 | 33 | 39 |
| Q1 2025 | 16 | 41 |
| Q2 2025 | 13 | 20 |
| Q3 2025 | 21 | 11 |
| Q4 2025 | 21 | 13 |
| Q1 2026 | 13 | 21 |
| Q2 2026 | 0 | 34 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2025 | $48.8k | $0 | 0.00 |
| Q4 2025 | $6.8k | $340 | 0.05 |
| Q1 2026 | $17.5k | $32 | 0.00 |
| Q2 2026 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| ACORN CAPITAL ADVISORS, LLC | Reduced | -5.3m |
| MILLENNIUM MANAGEMENT LLC | Sold out | -2.8m |
| VANGUARD CAPITAL MANAGEMENT LLC | Sold out | -1.6m |
| ACADIAN ASSET MANAGEMENT LLC | Sold out | -1.2m |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -689.2k |
| DEUTSCHE BANK AG\ | Sold out | -525.4k |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -510.5k |
| BlackRock, Inc. | Sold out | -480.9k |
| CITADEL ADVISORS LLC | Sold out | -435.7k |
| UBS Group AG | Sold out | -375.6k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| ACORN BIOVENTURES, L.P. 13G · passive investor filed 2025-05-20 | 8.3% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC 13G · institution -2.2 pts · filed 2025-04-25 | 7.7% |
| SHORT JAY M PHD 13G · exempt (held before listing) filed 2025-02-07 | 6.6% |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| ACORN CAPITAL ADVISORS, LLC 0.12% of their portfolio | 108.1k $447.6k | Reduced -5.3m |